Clinical Trial Update: Short Course of Miltefosine and Antimony to Treat Cutaneous Leishmaniasis in Bolivia [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update evaluating a short course of miltefosine and an antimony compound for cutaneous leishmaniasis in Bolivia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Leishmaniasis

Drugs mentioned

• Antimony (antimony compound)
• Miltefosine (miltefosine)

Snippet

Sponsor: Centro de Investigaciones Bioclínicas de la Fundación Fader | Conditions: Cutaneous Leihmaniasis | Phase 2 | Status: UNKNOWN